Fly News Breaks for November 21, 2019
Nov 21, 2019 | 09:29 EDT
H.C. Wainwright analyst Joseph Pantginis called Harpoon Therapeutics' (HARP) two-part deal with AbbVie (ABBV) "early, but impressive," noting that the first part provides AbbVie with an option to license worldwide rights to HPN217 and the second expands their existing collaboration to include up to six additional targets. Pantginis does not have a rating on Harpoon shares, though he maintains a Buy rating on Arix Bioscience, which counts Harpoon among its portfolio companies. On Arix, he reiterates his Buy rating and 314 pence price target, stating that he continues to see a significant disconnect between the share price and the company's net asset value for its 14 portfolio companies.
News For HARP;ABBV From the Last 2 Days
Dec 6, 2021 | 09:40 EST
Unusual total active option classes on open include: WeWork (WE), SPDR S&P Regional Banking (KRE), Ardelyx (ARDX), DocuSign (DOCU), Pinduoduo (PDD), Rocket Lab USA (RKLB), Global X Uranium (URA), Norwegian Cruise Line (NCLH), Chewy (CHWY), and AbbVie (ABBV).
Dec 6, 2021 | 08:32 EST
AbbVie announced positive top-line results from U-EXCEED, a Phase 3 induction study, showing upadacitinib achieved both primary endpoints of clinical remission and endoscopic response at week 12. The U-EXCEED study enrolled patients with moderate to severe Crohn's disease who had an inadequate response or were intolerant to biologic therapy, with over 60% having previously failed two or more biologics. U-EXCEED is the first of two Phase 3 induction studies to evaluate the safety and efficacy of upadacitinib in adults with moderate to severe Crohn's disease. "The data from this first Phase 3 induction study in Crohn's disease suggest upadacitinib may help address the needs of patients suffering from this disease, as demonstrated in stringent endpoints such as endoscopic response," said Michael Severino, M.D., vice chairman and president, AbbVie. "We continue to leverage our expertise in IBD by driving research and development that help shape the IBD landscape and elevate standards of care for patients."